UNSPSC 51385609: Potassium salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H5O3.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K91YT16P5M, chemically known as benzoic acid, 2-hydroxy-, monopotassium salt but generally known as potassium salicylate, which bears US NIH Compound Identifier 11355. European Medicines Agency schedules Potassium salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14994MIG.

World Health Organization schedules potassium salicylate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, POTASSIUM SALICYLATE remains the US FDA Preferred Term for this commodity. Potassium salicylate bears US NLM identifiers UMLS ID C0770438 and NCI Concept Code C84100. SMILES: C1=CC=C(C(=C1)C(=O)[O-])O.[K+].

UNSPSC 51385609 Potassium salicylate is a Commodity code, but recent state and local solicitations tagged with this code do not target potassium salicylate itself. Instead, they are procuring naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer pharmacy benefit programs — a mismatch between the code's nominal scope and the work actually being bought. The code shows minimal relevant recent activity under its stated commodity description.

Three recent opportunities in the source block illustrate the divergence. Seminole County, Florida released IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. None of these procurements align with potassium salicylate as a discrete product line. Procurement activity under this code warrants verification against the issuing body's actual scope or recoding before pursuit.